Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

Avodes-Biotech

Financiado

Avodes - biotechnological menstrual product for Candidiasis prevention

372 million women globally have a silent torturer - recurrent vulvovaginal candidiasis (VVC) , which affects 3 out of 4 women at some point in their lives. Despite therapeutic advances, VVC remains a common problem worldwide, affe... ver más

30/11/2022

UAB AVODES

75K€

Presupuesto del proyecto: 75K€

Líder del proyecto

UAB AVODES No se ha especificado una descripción o un objeto social para esta compañía.

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2022-11-30

HORIZON-EIE-2021-SCALEUP-01-03: Women TechEU ExpectedOutcome:

Innovación

Cerrada hace 3 años

0% 100% 100%

1 Participantes

UAB AVODES

75.00K€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

VMS - Vaginal Microbiome Screening Commercialisation and scale up of a Vaginal Microbiome Scree... 4M€ Cerrado

IPT-2012-0698-010000 DESARROLLO DE KIT DE MULTIDIAGNÓSTICO DE ENFERMEDADES VAGINA... 443K€ Cerrado

WOMED WOMED: an innovative intrauterine biodegradable polymer-base... 4M€ Cerrado

SME-2017-0946-10 COLLECTION DEVICE FOR KEEPING MICROBIOTA VIABILITY 57K€ Cerrado

AVeta Hormone-free solution for vaginal atrophy 4M€ Cerrado

CNS2023-145286 Fisiopatología de órganos y sistemas 200K€ Cerrado

Duración del proyecto: 6 meses Fecha Inicio: 2022-05-16
Fecha Fin: 2022-11-30

Líder del proyecto

UAB AVODES No se ha especificado una descripción o un objeto social para esta compañía.

Presupuesto del proyecto 75K€

Descripción del proyecto 372 million women globally have a silent torturer - recurrent vulvovaginal candidiasis (VVC) , which affects 3 out of 4 women at some point in their lives. Despite therapeutic advances, VVC remains a common problem worldwide, affecting all strata of society and being the second largest gynaecological infection. If it is left untreated, many complications have been appointed as its consequence, such as infertility, subsequent preterm delivery, suppression of the immune system, pelvic inflammatory disease, ectopic pregnancy, pelvic abscess, menstrual disorders and miscarriage. Avodes has developed an innovative medical device for menstruation - a patented anatomically shaped moist sponge made of completely natural, biodegradable materials (biodegradable within 1 month). It protects innate defence mechanisms of vaginal microflora during most vulnerable period – menstruation. Studies have shown, that fluctuating hormones and the resulting imbalance of vaginal flora cause an increased risk of a yeast infection every month. Unique Avodes biotechnological solution preserves women’s natural vaginal microbiota in the same time selectively inhibiting growth of pathogenic microorganisms. It reduces risk of vulvovaginal candidiasis (VVC) by 85 % thus effectively preventing the disease. Avodes is the only medical product designed to prevent infection, rather than deal with the consequences. Avodes effectively disrupts the vicious cycle of microbiota disbalance –> infection –> antibiotic/fungicidal treatment–> microbiota disbalance and offers break-through solution which protects women’s health and the environment. Women Tech EU programme would support company in upgrading the business model, business and marketing plan, market validation and would help to find partners (clinical, manufacturing and commercial) as well as to prepare funding strategy. Successful project implementation will provide much needed tailwind to our company to bring the product to the market.

Conecta tu I+D

Entra hoy

¿Olvide mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores